Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Transcript
Small cell cancer is a type of lung cancer that presents in basically two formats. One format is that the disease is actually limited to what classically, in the old days, radiation oncologists called “the box,” meaning that it was limited to the chest. When we talk about limited stage small cell carcinoma, we’re talking, potentially, about a disease that is very responsive to treatment, and sometimes can be cured. When we cure those patients, with a combination of chemotherapy and radiation for limited stage small cell carcinoma, we often look to see if the cancer has spread to the brain. We do this by getting MRI studies of the brain; if there’s no evidence of disease in the brain, and the treatment has effectively worked in the chest at eradicating the disease, we all are very happy.
Unfortunately, if you follow these patients over time, they have a very high chance of having the cancer come back in the brain — the brain is thought to be a sanctuary site, meaning that it doesn’t get the treatment from the chemotherapy that the rest of the body gets, so if any cells have snuck up there, they sometimes can grow without the treatment that’s been delivered so far.
One of the things that we’ve done in the past is deliver a very low dose of radiation to the whole brain, as a prophylactic treatment — that’s often called PCI, or prophylactic cranial irradiation. We offer this routinely to patients with limited stage disease because the studies have demonstrated that if you give prophylactic treatment, you reduce the chances of the cancer coming back in the brain, and if you reduce the chances of the cancer coming back in the brain, you presumably reduce the chances of all those symptoms that cancer in the brain can cause.
We often talk about the brain as being the “high rent district.” If we can keep cancer out of the brain, we can keep people much more functional, not have the risks of strokes, and mental problems, and seizures that cancer in the brain can cause, so we often give prophylactic cranial irradiation.
Prophylactic cranial irradiation is a little bit different than whole brain radiation: the doses that you give each day are lower, the dose that you give overall is lower, because you’re treating disease that you can’t see, you’re not treating the disease that is actually already there — hence the word prophylactic cranial irradiation.
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: